The MarketWatch News Department was not involved in the creation of this content. New retrospective analysis showed Orca-T with reduced intensity conditioning (RIC) demonstrated favorable OS, RFS and ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ...

Orca Bio to Present Clinical Data on Its Pipeline of High-Precision Cell Therapies at the 52nd Annual Meeting of the EBMT Patient reported outcomes with Orca-T® from the pivotal Precision-T Phase 3 ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to July 6. The review extension comes after the company submitted additional data ...

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

The FDA grants RMAT designation to Orca-Q, Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy.

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the appointment of Bijan Nejadnik, M.D., as Chief ...

New PDUFA Target Action Date of July 6, 2026 allows FDA additional time to complete its review Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high ...

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ...